Kornimate/medical-research-clean huggingface dataset:
evaluation of oesogastroduodenoscopy with vision to 245 ° (full spectrum endoscopy) to view the main disc and accessory

Conditions: Adenoma of the Accessory Papilla; Ampulloma of the Accessory Papilla

Summary: the monitoring and prognosis of patients with familial polyposis adenomatous rests on analysis of the transitional mucosa at the anal margin and especially on the tracking, characterization and resection of lesions of dysplasia type of high grade at the duodenal level, after total proctocolectomy. currently, endoscopes with axial or lateral vision are used. the fuse technology allows the simplification or even the improvement of patient surveillance with a 245° vision (versus150° in case of classical gastroscope). the use of a second screen to enlarge the field of view may allow both analysis of duodenum and the main and accessory papilla with one single endoscope and to decrease the number of omitted lesions .


Eligibility criteria:
inclusion criteria: * patient eligible to any upper gastrointestinal endoscopy diagnostic exclusion criteria: * history of duodenal or gastric surgery
intra-oral camera in gingival health

Conditions: Gingival Hemorrhage; Gingivitis; Health Behavior; Communication

Summary: evaluate the effects of using an intra-oral camera (ioc) during supportive periodontal therapy (spt), on the psychological, behavioral and clinical parameters of patients with gingivitis, outlined by evidence and a theory-based framework.

a group of 78 adult patients with gingivitis receiving an spt was randomized into two groups: ioc and control. bleeding on marginal probing (bomp), self-reported dental hygiene behaviors, and psychological determinants of behavior change (outcome expectancies, self-efficacy and planning) and ioc opinion were evaluated one week before or during the consultation and four months later.

Eligibility criteria:
inclusion criteria: * \>18 years old. * + 20 teeth (minimum 5 per quadrant) * bomp \> 0.5 exclusion criteria: * periodontitis (pockets \>4), * smoking patients * orthodontic patients * pregnant * 1 removable partial denture

Keywords: gingivitis oral hygiene intra oral camera self regulation bleeding
pulmonary hypertension in patients attending sohag university hospital: a focus on the etiology

Conditions: Patients With Pulmonary Hypertension

Summary: assessment of pulmonary hypertension in patients attending sohag university hospital ( in out patient clinic or in patient) focusing on the etiology of pulmonary hypertension


Eligibility criteria:
inclusion criteria: * patients who are 18 years old or more * patients with pulmonary hypertension diagnosed with echocardiography exclusion criteria: * patient who are less than 18 years old
an active approach to treat amblyopia: perceptual learning and video games

Conditions: Amblyopia

Summary: amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. this study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia.

amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. our previous findings (see citations) show that the adult amblyopic brain is still plastic and malleable, suggesting that active approach is potential useful in treating amblyopia. the goal of this project is to assess the limits and mechanisms of neural plasticity in both normal and amblyopic spatial vision. this study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia. research participants will be asked to practice a visual discrimination task (perceptual learning) or to play video games with the amblyopic eye for a period of time. a range of visual functions will be monitored during the course of treatment.

Eligibility criteria:
inclusion criteria: * adults and children (\>5 years old) with normal vision or amblyopia * amblyopia: interocular va difference of at least 0.1 logmar exclusion criteria: * any ocular pathological conditions, nystagmus

Keywords: amblyopia treatment neural plasticity perceptual learning vision therapy spatial vision video games occlusion therapy
non-invasive quantification of atrial fibrosis by mri in atrial fibrillation

Conditions: Atrial Fibrillation

Summary: three groups of patients will be considered: a control group (n = 10); a group of patients with paroxysmal or persistent af with af cryoablation procedure - within this group, mri will replace ct-scan usually performed in routine before the procedure (n = 15); a group of patients with permanent af (n = 15). mri study will include pulmonary veins angiography with gadolinium injection (0.20 mmol/kg), 2d-cine imaging and late-enhancement imaging. a 3d gradient-echo sequence(flash 3-d) will then be applied 20 minutes after the injection, with the following parameters : echo time 0.98 ms, repetition time 2.53 ms, angle 15°, resolution 2.0x1.3x1.0 mm. t1 map and two t2 sequences will be performed so as to determine la relaxation times. argus software will be used for post-treatment imaging. quantitative data will be expressed in mean ± sd. a comparison of t1 and t2 values in la will be performed between the three groups. statistics will be performed with spss software in bilateral analysis and a value of p \< 0.05 will be considered as significant.


Eligibility criteria:
inclusion criteria: all persons \> 18 years, which have: gp paroxysmal or persistant fa 1. paroxysmal or persistent fa (under one year), 2. refractory to at least one antiarrhythmic drug therapy 3. eligible for an ablation procedure with cryotherapy 4. the patient may benefit from surveillance. gp permanent fa permanent af ( defined as chronic arrhythmia after 2 failed attempts to electrical cardioversion and / or more than one year old) , and hospitalized for cardiac reasons or not in different cardiology timone . exclusion criteria: * age \< 18 years, * cons -indications to mri ( claustrophobia, pacemakers and implantable cardiac defibrillators , metal chips intra ocular , valvular mechanical prosthesis ) , allergy to gadolinium , * renal impairment ( creatinine clearance \<60 ml / min) * pregnant or nursing ( a pregnancy test must be performed for women of childbearing age at the time of inclusion , the result of this test will be communicated to them . * the mri examination takes place three months after the inclusion women of childbearing potential should be placed under effective contraception)
mitralign percutaneous annuloplasty system for chronic functional mitral valve regurgitation

Conditions: Mitral Valve Regurgitation

Summary: the purpose of this study is to test the safety and device performance of the mitralign system ("mpas") to treat functional mitral valve regurgitation.

the align study is a single arm, prospective study. the objective of the study is to investigate the safety and performance of a catheter-based plication device intended to reduce the circumference of the dilated mitral valve. the study will enroll up to 50 subjects from up to 5 sites (paraguay, columbia, dominican republic, brazil, and india) who will be followed for 36 months post index procedure. enrollment is defined at the time the study device is inserted into the body and patients will be followed at 30 days, and months 6, 12, 24 and 36 post index procedure.

Eligibility criteria:
inclusion criteria: * nyha ii-iv * structurally normal mitral valve * at least grade 2 mitral regurgitation * left ventricular ejection fraction not less than 20% and not greater than 45% * left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5 cm exclusion criteria: * pregnant or lactating female * mitral stenosis * mod/severe aortic stenosis or regurgitation * mod/severe tricuspid stenosis or regurgitation * endocarditis * previous mitral valve repair or mv replacement * bioprosthetic or mechanical aortic valve * known unstable angina or mi within 30 days prior to procedure * cva within past 6 months * known contraindications to blood transfusion, contrast dye, dapt

Keywords: mitral valve, regurgitation, annuloplasty
effect of ophiochepalus striatus extract on serum igf-1 and il-6 levels in elderly patients with sarcopenia

Conditions: Sarcopenia; Geriatric; Muscle Mass; Muscle Strength; Physical Performance

Summary: the goal of this clinical trial is to analyze effect of ophiochepalus striatus extract on serum igf-1 and il-6 levels in elderly patients with sarcopenia. the main questions it aims to answer are: 1. can giving ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks increase igf-1 levels in elderly people with sarcopenia? 2. can administration of 2x5 grams dose of ophiocephalus striatus extract for 2 weeks reduce il-6 levels in elderly with sarcopenia? 3. can the administration of ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks reduce the sarc-f score in elderly people with sarcopenia? 4. can the administration of ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks increase muscle mass in elderly people with sarcopenia? 5. can the administration of ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks increase muscle strength in elderly people with sarcopenia? 6. can administration of ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks improve physical performance in elderly with sarcopenia? participants will: 1. consume ophiochepalus striatus extract 2x5 grams a day. 2. checked blood before and after the intervention. 3. measured muscle mass, muscle strength, and physical performance before and after the intervention.


Eligibility criteria:
inclusion criteria: * elderly patients with sarcopenia diagnosed using awgs criteria consist of low muscle mass: using the bia examination tool where men: \<7.0kg/m2, women: \<5.7kg/m2 plus low muscle strength using a handgrip dynamometer, men: \<28kg , female : \<18kg or low physical performance using the 6 meter walk test; \<1 meter/second. exclusion criteria: * chronic liver disease (cirrhosis of the liver) or severe liver dysfunction or increased sgpt\> 3 times the upper limit of normal value * impaired kidney function with a glomerular filtration rate \<30 ml/minute without hemodialysis * acute phase of illness (eg infection, acute arthritis, acute stroke, trauma) * malignancy * depression according to the geriatric depression scale (geriatric depression scale score\> 10) * history of hypersensitivity to ophiocephalus striatus * refuse to participate in research
phase ii open label study using triheptanoin in patients with glucose type 1 transporter deficiency glut1-ds

Conditions: Glut1 Deficiency Syndrome

Summary: the purpose of this project is to study the efficacy of triheptanoin oil in patients with glut1 deficiency syndrome.

the primary objective of the study is: - to evaluate the capacity of triheptanoïn to improve the condition of patients with glut1-ds the secondary objectives of the study are: * to confirm the short-term safety of triheptanoïn therapy in patients with glut1-ds * to evaluate the short-term effects of triheptanoïn treatment on motor function, autonomy, quality of life and clinical signs of patients with glut1-ds * to evaluate the effect of triheptanoïn on brain energy metabolism using non-invasive 31p-mrs spectroscopy after activation of the occipital cortex in order to measure the levels of high-energy phosphates (such as atp and phosphocreatine)

Eligibility criteria:
inclusion criteria: * mutation in slc2a1 gene * age \> 3 years * patient with history/frequency of seizures or movement disorders documented at least 3 months prior to the beginning of the study * covered by french social security * patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent. (in addition to the requirement for the consent of parents or the legal representative, adolescents can provide additional informed consent to participate in clinical trials) exclusion criteria: * evidence of psychiatric disorder * attendant neurological disorder * comorbid medical condition that would render them unsuitable for the study, e.g. hiv, diabetes * pregnant or parturient or lactating women * unwillingness to be informed in case of abnormal mri * failure to give written informed consent * unable to understand the protocol * unable to participate to the whole study * absence of signed informed consent * persons deprived of their liberty by judicial or administrative decision * person subject to an exclusion period for another research * subjects with exclusion criteria required by french law
safety and efficacy of tcd-10023 (ultimaster) drug-eluting stent in stemi patients - master study

Conditions: Acute ST Segment Elevation Myocardial Infarction

Summary: the aim of the study is to demonstrate the safety and efficacy of the tcd-10023 (ultimaster) sirolimus eluting stent in patients with acute st-elevation myocardial infarction (stemi), by proving superiority with respect to in-stent late loss at 6 months to the kaname bare metal stent and non-inferiority with respect to target vessel failure (tvf) at 12 months.

master is prospective, randomized (3:1), single blind, controlled, superiority (efficacy) and non-inferiority (safety and efficacy), multi center, two-arm trial of tcd-10023 (ultimaster) drug eluting stent (test) and kaname bare metal stent (comparator). patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 3 years. 500 patients with clinical follow up will be randomized in 3:1 ratio (375 in tcd-10023 arm and 125 in kaname arm). among them, 100 patients will be randomized in the same, 3:1 ratio, to angiographic follow up at 6 months in preselected hospitals (75 in tcd-10023 and 25 in kaname arm)

Eligibility criteria:
inclusion criteria: * age equal or more than 18 years * chest pain \> 20 minutes * primary pci \<24h from symptoms onset * st-segment elevation of \> 1 mm in \> 2 contiguous leads, or (presumably new) left bundle branch block, or true posterior mi with st depression of \> 1 mm in \> 2 contiguous anterior leads * presence of at least one acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery from 2.5-4.0 mm in diameter that can be covered with one or multiple stents * signed informed consent exclusion criteria: * female of childbearing potential (age \< 50 and last menstruation within the last 12 months), who did not underwent tubal ligation, ovariectomy or hysterectomy * known intolerance to aspirin, clopidogrel, heparin, bivalirudin, cobalt, chromium, nickel, sirolimus or contrast material * currently participating in another trial before reaching primary endpoint * mechanical complication of acute myocardial infarction (e.g. cardiogenic shock...) * acute myocardial infarction secondary to stent thrombosis * previously stented infarction related artery (ira) * planned surgery within 6 months of pci unless dual antiplatelet therapy is maintained throughout the peri-surgical period * patients with non-cardiac comorbid conditions with life expectancy\< 1 year or that may result in protocol non-compliance * history of bleeding diathesis or known coagulopathy * use of oral anticoagulants

Keywords: des pci stemi interventional cardiology
efficacy of distant healing in glioblastoma treatment

Conditions: Glioblastoma

Summary: this study will assess whether distant healing effects survival time and loss of function for glioblastoma patients.

prayer, energy healing, and spiritual healing are widely used for all degrees of illness. eisenberg (1998) reported that more that 26% of his survey sample used "energy healing" within the last year. most of these practitioners believe that their inner intentions result in the benefits, either through the agency of love, energy, or a higher power (benor 1992). however, the conventional community attributes benefits from these interventions to the patient's hope, expectation, or experience of support from a practitioner (benson 1996). the proposed study is a double-blind randomized controlled clinical trial of "distant healing intentionality." distant healing (dh) is defined as a "mental intention on behalf of one person, to benefit another at a distance." this study will assess whether dh effects survival time and loss of function for glioblastoma patients under conditions where hope and expectation are controlled. the study will include approximately 150 patients who have rapidly progressing glioblastoma and are beginning radiotherapy. patients will be photographed and assessed for quality of life, psychological status, and physical symptoms as well as health habits and attitude toward dh. after stratification by age and functional status (karnofsky score), patients will be randomly assigned to either standard treatment with or without dh. healers from diverse schools and backgrounds from communities across the united states will be assigned to patients by rotation, so that each patient in the dh group will be treated for two weeks by 10 different healers over the 20 week intervention. experienced healers will have photographs of subjects and send "mental intention for health and well being" to subjects for one hour daily, three times per week. the healing intervention will be performed at a distance, and patients and healers will never meet, nor will patients know their group assignment. the study findings will provide the basis for developing a larger study, definitive trial.

Eligibility criteria:
inclusion: * histologically confirmed diagnosis of glioblastoma based on open resection. * patient is within five weeks of diagnosis confirmed by pathology report. exclusion: * non-english speaking. * inability or unwillingness to fill out questionnaires. * history of other cancers within the last 2 years (except superficial basal cell, squamous cell carcinoma of the skin), or other concurrent life-threatening conditions.

Keywords: glioblastoma brain tumor distant healing distance healing
the emergency department sedation pilot trial

Conditions: Mechanical Ventilation; Respiratory Failure

Summary: the ed-sed pilot is a multicenter, prospective, before-and-after study conducted on 344 mechanically ventilated emergency department patients at three academic medical centers: washington university in st. louis school of medicine (st. louis, mo), cooper hospital of rowan university (camden, nj), and university of iowa carver college of medicine (iowa city, ia). the overall goal is to assess the feasibility of implementing targeted sedation (in terms of sedation depth) for mechanically ventilated ed patients in order to reduce the incidence of unnecessary deep sedation and improve clinical outcomes.

the ed-sed pilot is a multicenter, prospective, before-and-after study conducted on 344 mechanically ventilated ed patients at three academic medical centers. patients in the before phase of the study will receive usual care after the initiation of mechanical ventilation. after 172 patients have been enrolled in the before phase, the investigators will begin educational initiatives to implement ed-based sedation protocols and order sets. the research team will educate providers on the importance of sedation protocols on patient outcome so that the existing protocols begin to be used effectively in the ed. this educational initiative will allow targeted sedation to be effectively used in the ed as well, allowing the intervention to be tested under real-world conditions. participants in the after phase will also receive standard post-intubation care at the discretion of the treating team, though it will be after the educational initiative aimed at improving post-intubation sedation. in order to more effectively use sedation in the ed, the investigators will collect voluntary and anonymous surveys from ed nurses and physicians to assess the potential facilitators and barriers to adherence to guideline-recommended sedation.

Eligibility criteria:
inclusion criteria: 1. mechanical ventilation via an endotracheal tube. 2. age ≥ 18 years. exclusion criteria: 1. acute neurologic injury (stroke, intracranial hemorrhage, traumatic brain injury, cardiac arrest, status epilepticus, fulminant hepatic failure). 2. ongoing neuromuscular blockade. 3. death or transition to comfort measures within 24 hours. 4. transfer to another hospital from the ed. 5. chronic/home mechanical ventilation. 6. transfer directly from the ed to the operating room.

Keywords: sedation mechanical ventilation emergency department rass
transcranial direct current stimulation for impulsivity and food-related impulsivity in obesity

Conditions: Impulsive Behavior

Summary: in this study the investigators aim to assess whether transcranial direct current stimulation (tdcs; a safe non-invasive method for modulating the activity of specific brain regions) when applied over the orbitofrontal cortex (ofc) is able to modulate impulsivity in obese participants.

in this single-blind, sham controlled study, the investigators will assess whether transcranial direct current stimulation (tdcs; a safe non-invasive method for modulating the activity of specific brain regions) when applied over the orbitofrontal cortex (ofc) is able to modulate impulsivity in obese volunteers. the investigators hypothesize that tdcs applied to the ofc, in comparison to sham tdcs, will significantly reduce impulsivity and enhance decision making as measured by computerized neurocognitive tasks. for this study the investigators will enroll 30 obese individuals aged 18-65 years. participants will be assessed with a battery of computerized tasks as well as self-reported questionnaires on eating, impulsivity, mood and anxiety. assessments will be carried out before, during, and after a single 20-minute 2ma tdcs session.

Eligibility criteria:
inclusion criteria: * men or women aged 18 to 65 * have body mass index of 35 or above * have had no recent change in medications in the 2 weeks prior participating in the study * able to fast for 4 hours prior participating in the study exclusion criteria: * active substance use disorder * active suicidal ideation * psychoactive medication * past or current gambling disorder * past or current anorexia * past or current bulimia nervosa * past or current psychosis * visual impairments preventing performance of the neuropsychological tasks * epilepsy * traumatic brain injury * stroke * neurological disorder affecting motor functions (parkinsons, huntington's, etc) * previous participation in tdcs research/treatment
f adding ketamine to propofol for drug-induced sleep endoscopy in adult patients with obstructive sleep apnea

Conditions: Sleep Apnea Syndromes

Summary: the investigator compared the sedative effects of propofol alone and ketamine added to propofol in drug induced sleep endoscopy

propofol and ketamineare commonly used intravenous anesthetic drug used for procedural sedation. the investigator compared the effect of propofol and propofol ketamine in patients undergoing drug induced sleep endoscopy.

Eligibility criteria:
inclusion criteria * age \> 18 years old. * american society of anesthesiologists (asa) physical status i or ii. i / ii exclusion criteria: * patient refusal * american society of anesthesiologists (asa) physical status \> iii * known or suspected allergy to the studied drugs or its components, allergy to eggs or soy beans * morbid obesity * patients with moderate to severe chronic obstructive pulmonary disease or uncontrolled asthma, congestive e heart failure ,seizures ,or cerebrovascular disease * pregnancy